Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has earned an average recommendation of “Buy” from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $61.80.
Several brokerages recently weighed in on TRML. Jefferies Financial Group raised their price target on shares of Tourmaline Bio from $41.00 to $72.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $48.00 price target on shares of Tourmaline Bio in a research report on Tuesday, May 14th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $74.00 price target on shares of Tourmaline Bio in a research report on Monday, March 25th.
View Our Latest Report on Tourmaline Bio
Institutional Investors Weigh In On Tourmaline Bio
Tourmaline Bio Price Performance
TRML stock opened at $12.74 on Tuesday. The stock has a market capitalization of $326.78 million, a PE ratio of -1.96 and a beta of 2.30. The company’s 50-day moving average is $14.75 and its 200-day moving average is $25.23. Tourmaline Bio has a 1 year low of $9.18 and a 1 year high of $48.31.
Tourmaline Bio (NASDAQ:TRML – Get Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.13. On average, analysts anticipate that Tourmaline Bio will post -2.94 earnings per share for the current fiscal year.
About Tourmaline Bio
Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
Featured Articles
- Five stocks we like better than Tourmaline Bio
- Comparing and Trading High PE Ratio Stocks
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Find Undervalued Stocks
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Tourmaline Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tourmaline Bio and related companies with MarketBeat.com's FREE daily email newsletter.